These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 8003557)
1. Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment. Seipelt G; Ganser A; Duranceyk H; Maurer A; Ottmann OG; Hoelzer D Ann Hematol; 1994 Apr; 68(4):167-70. PubMed ID: 8003557 [TBL] [Abstract][Full Text] [Related]
2. Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF. Zwierzina H; Herold M; Schöllenberger S; Geissler D; Schmalzl F Br J Haematol; 1991 Nov; 79(3):438-43. PubMed ID: 1751371 [TBL] [Abstract][Full Text] [Related]
3. Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. Ogata K; Yokose N; An E; Kamikubo K; Tamura H; Dan K; Sakamaki H; Onozawa Y; Hamaguchi H; Nomura T Br J Haematol; 1996 Apr; 93(1):45-52. PubMed ID: 8611474 [TBL] [Abstract][Full Text] [Related]
4. Plasma soluble interleukin-2 receptors in patients with myelodysplastic syndromes. Yokose N; Ogata K Leuk Lymphoma; 1997 Dec; 28(1-2):171-6. PubMed ID: 9498716 [TBL] [Abstract][Full Text] [Related]
6. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes. Yokose N; Ogata K; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T Leuk Res; 1994 Oct; 18(10):777-82. PubMed ID: 7934136 [TBL] [Abstract][Full Text] [Related]
7. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Berghella AM; Pellegrini P; Del Beato T; Marini M; Tomei E; Adorno D; Casciani CU Cancer Immunol Immunother; 1998 Jan; 45(5):241-9. PubMed ID: 9439647 [TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066 [TBL] [Abstract][Full Text] [Related]
9. Cytokine profile during high-dose rhG-CSF therapy in severe congenital neutropenia. Shitara T; Yugami S; Ijima H; Sotomatu M; Kuroume T Am J Hematol; 1994 Jan; 45(1):58-62. PubMed ID: 7504401 [TBL] [Abstract][Full Text] [Related]
10. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma. Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325 [TBL] [Abstract][Full Text] [Related]
11. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: effect of interferon therapy. Simsek H; Kadayifci A J Int Med Res; 1996; 24(3):239-45. PubMed ID: 8725984 [TBL] [Abstract][Full Text] [Related]
12. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. Symons JA; Wood NC; Di Giovine FS; Duff GW J Immunol; 1988 Oct; 141(8):2612-8. PubMed ID: 3262665 [TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Nimer SD; Paquette RL; Ireland P; Resta D; Young D; Golde DW Exp Hematol; 1994 Aug; 22(9):875-80. PubMed ID: 8062886 [TBL] [Abstract][Full Text] [Related]
14. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122 [TBL] [Abstract][Full Text] [Related]
15. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms. Bodey B; Psenko V; Lipsey AL; Kaiser HE Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612 [TBL] [Abstract][Full Text] [Related]
16. [Soluble interleukin 2 receptor (sIL-2R) in patients with esophageal carcinoma]. Duan ZF Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):17-9. PubMed ID: 8334935 [TBL] [Abstract][Full Text] [Related]
17. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice. Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932 [TBL] [Abstract][Full Text] [Related]
18. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Gooding R; Riches P; Dadian G; Moore J; Gore M Br J Cancer; 1995 Aug; 72(2):452-5. PubMed ID: 7640231 [TBL] [Abstract][Full Text] [Related]
19. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570 [TBL] [Abstract][Full Text] [Related]
20. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2. Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]